Tyrosine Kinase Inhibitor Enhances the Bioavailability of Oral Irinotecan in Pediatric Patients With Refractory Solid Tumors

PURPOSE: To assess the maximum-tolerated dosages (MTDs), and dose-limiting toxicities (DLTs) of the epidermal growth factor receptor inhibitor gefitinib and of intravenous (IV) irinotecan when administered together in children with refractory solid tumors. To assess the effect of gefitinib on the ph...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Furman, Wayne L., Navid, Fariba, Daw, Najat C., McCarville, M. Beth, McGregor, Lisa M., Spunt, Sheri L., Rodriguez-Galindo, Carlos, Panetta, John C., Crews, Kristine R., Wu, Jianrong, Gajjar, Amar J., Houghton, Peter J., Santana, Victor M., Stewart, Clinton F.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2009
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2754908/
https://ncbi.nlm.nih.gov/pubmed/19687340
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.19.6642
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados